In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39.9 ± 8.3 years, 43 % males). After five consecutive years of therapy, patients on deferasirox had the highest decrease in the prevalence of any endocrinopathy compared to other chelators which either had no change (deferiprone and deferoxamine) or had an increase (deferoxamine + deferiprone), p = 0.015. This was attributed to a lower proportion of patients on deferasirox developing new-onset endocrinopathy and higher proportion showing reversal of disease, compared to other chelators. A serum ferritin level of >1300 ng/mL predicted the development of new endocrinopathy (p = 0.025) while a level of <200 ng/mL predicted reversal of existing endocrinopathy (p = 0.147). A significant increase in mean BMD T-score (p < 0.001) and a considerable decrease in osteoporosis prevalence were observed in patients receiving deferasirox but not other chelators. Iron chelation therapy with deferasirox has a role in the prevention of endocrinopathy and reversal of existing disease.

Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years / Poggi, Maurizio; Sorrentino, Francesco; Pugliese, Pellegrina; Smacchia, Maria Paola; Daniele, Carmine; Equitani, Francesco; Terlizzi, Filomena; Guitarrini, Maria Rita; Monti, Salvatore; Maffei, Laura; Losardo, Anna; Pasin, Methap; Toscano, Vincenzo. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - ELETTRONICO. - 95:5(2016), pp. 757-763. [10.1007/s00277-016-2633-y]

Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years

Smacchia, Maria Paola;Daniele, Carmine;Monti, Salvatore;Toscano, Vincenzo
2016

Abstract

In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39.9 ± 8.3 years, 43 % males). After five consecutive years of therapy, patients on deferasirox had the highest decrease in the prevalence of any endocrinopathy compared to other chelators which either had no change (deferiprone and deferoxamine) or had an increase (deferoxamine + deferiprone), p = 0.015. This was attributed to a lower proportion of patients on deferasirox developing new-onset endocrinopathy and higher proportion showing reversal of disease, compared to other chelators. A serum ferritin level of >1300 ng/mL predicted the development of new endocrinopathy (p = 0.025) while a level of <200 ng/mL predicted reversal of existing endocrinopathy (p = 0.147). A significant increase in mean BMD T-score (p < 0.001) and a considerable decrease in osteoporosis prevalence were observed in patients receiving deferasirox but not other chelators. Iron chelation therapy with deferasirox has a role in the prevention of endocrinopathy and reversal of existing disease.
2016
diabetes; hypogonadism; hypothyroidism; iron overload; osteoporosis; adult; benzoates; deferoxamine; diabetes mellitus; drug therapy, combination; female; follow-up studies; humans; hypogonadism; hypothyroidism; iron chelating agents; iron overload; male; middle aged; osteoporosis; prevalence; pyridones; retrospective studies; transfusion reaction; triazoles; beta-thalassemia; chelation therapy; hematology
01 Pubblicazione su rivista::01a Articolo in rivista
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years / Poggi, Maurizio; Sorrentino, Francesco; Pugliese, Pellegrina; Smacchia, Maria Paola; Daniele, Carmine; Equitani, Francesco; Terlizzi, Filomena; Guitarrini, Maria Rita; Monti, Salvatore; Maffei, Laura; Losardo, Anna; Pasin, Methap; Toscano, Vincenzo. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - ELETTRONICO. - 95:5(2016), pp. 757-763. [10.1007/s00277-016-2633-y]
File allegati a questo prodotto
File Dimensione Formato  
Poggi_Longitudinal_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 361.27 kB
Formato Adobe PDF
361.27 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1078181
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 51
social impact